Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis
Alentis Appoints Alberto Toso Chief Scientific Officer
William Pao Joins Alentis Therapeutics as Independent Board Member
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointed Chief Business Officer (CBO). He will lead corporate strategy, business development, and finance.
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced the first patient dosed in a Phase 2 clinical trial of lixudebart (formerly named ALE.F02), a Claudin-1 (CLDN1) targeting investigational antibody for the treatment of organ fibrosis.
Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04
Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today an oral presentation during the ERS International Congress to be held September 9-13 in Milan, Italy.
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis’ board.